|
| 产地 | 中国 |
| 品牌 | Chemstan |
| 货号 | LC-01 |
| 用途 | 中间体 |
| 包装规格 | 20mg |
| 纯度 | 98%% |
| CAS编号 | 110078-46-1 |
| 是否进口 | 否 |
联合知名大学科研院所及企业开发药食两用植物标准品和天然植物有效单体，主打中药对照品/标准品/天然植物有效单体，小分子化合物库，药物杂质。所有产品仅用作科学研究，我们不为任何个人用途提供产品和服务。
| 常用名 | 普乐沙福 | 英文名 | Plerixafor |
|---|---|---|---|
| CAS号 | 110078-46-1 | 分子量 | 502.782 |
| 密度 | 1.0±0.1 g/cm3 | 沸点 | 657.5±55.0 °C at 760 mmHg |
| 分子式 | C28H54N8 | 熔点 | 122-125°C |
| MSDS | N/A | 闪点 | 361.8±26.2 °C |
Plerixafor是选择性的 CXCR4 拮抗剂，IC50值为44 nM。
Fields of Application :
Plerixafor is a chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with IC50 of 44 nM and 5.7 nM, respectively.
| CAS Number: | 110078-46-1 |
| Purity: | >98% |
| Molecular Weight: | 502.78 |
| Molecular Formula: | C28H54N8 |
Quality Control: HPLC、NMR、 LC/MS(Please contact us to get the QC report)
| Synonyms: | 1,4,8,11-Tetraazacyclotetradecane, 1,1'-[1,4-phenylenebis(methylene)]bis,AMD 3100,AMD-3100 |
| Chemical Name: | |
| Storage: | 2 years -20°C Powder, 2 weeks4°C in DMSO,6 months-80°C in DMSO |
Note: Products for research use only, not for human use
Description:
Plerixa For inhibits CXCL12-mediated chemotaxis with a potency lightly better than its affinity For CXCR4. Plerixa For also antagonizes SDF-1/CXCL12 ligand binding with an IC50 of 651 nM. Plerixa For inhibits SDF-1 mediated GTP-binding, SDF-1 mediated calcium flux and SDF-1 stimulated chemotaxis with IC50 of 27 nM, 572 nM and 51 nM, respectively. Plerixa For does not inhibit calcium flux against cells expressing CXCR3, CCR1, CCR2b, CCR4, CCR5 or CCR7 when stimulated with their cognate ligands, nor does Plerixa For inhibit receptor binding of LTB4. Plerixa For does not, on its own, induce a calcium flux in the CCRF–CEM cells, which express multiple GPCRs including CXCR4, CCR4 and CCR7. A single topical application of Plerixa For promotes wound healing in diabetic mice by increasing cytokine production, mobilizing bone marrow EPCs, and enhancing the activity of fibroblasts and monocytes/macrophages, thereby increasing both angiogenesis and vasculogenesis. Cohorts of mice are administered with PBS, IGF1, PDGF, SCF, or VEGF For five consecutive days and Plerixa For on the 5th day. The number and size of the colonies are highest in IGF1 plus Plerixa For injected mice compared to PDGF, SCF and VEGF treated groups, in combination with Plerixa For. For the detailed information of Plerixafor (AMD3100), the solubility of Plerixafor (AMD3100) in water, the solubility of Plerixafor (AMD3100) in DMSO, the solubility of Plerixafor (AMD3100) in PBS buffer, the animal experiment (test) of Plerixafor (AMD3100), the cell expriment (test) of Plerixafor (AMD3100), the in vivo, in vitro and clinical trial test of Plerixafor (AMD3100), the EC50, IC50,and Affinity of Plerixafor (AMD3100), Please contact DC Chemicals.
